tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway
PremiumRatingsAnalyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway
11d ago
Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year
Premium
The Fly
Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year
12d ago
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
Premium
Company Announcements
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
24d ago
Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
PremiumRatingsAlec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
3M ago
Vir Biotechnology Announces Board Changes and Shareholder Approvals
Premium
Company Announcements
Vir Biotechnology Announces Board Changes and Shareholder Approvals
3M ago
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
Premium
The Fly
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial
3M ago
Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
PremiumThe FlyVir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
3M ago
Analyst Reiterates Buy on Vir Biotechnology, Citing Best-in-Class HDV Profile and Maintaining $18 Price Target
Premium
Ratings
Analyst Reiterates Buy on Vir Biotechnology, Citing Best-in-Class HDV Profile and Maintaining $18 Price Target
4M ago
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update
Premium
Company Announcements
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100